Evaluation of residual CD34+Ph+ progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy

Cancer, 04/24/2012

This study assessed for the first time the persistence of CD34+Ph+ cells during nilotinib first–line treatment. Preliminary results showed that in patients in CCyR, even after short–term nilotinib therapy, residual leukemic progenitors are very rarely detected compared with imatinib–treated CCyR patients.

Print Article Summary Cat 2 CME Report